ArticleAmerican journal of physiology. Heart and circulatory physiology2025
Bone morphogenetic protein 10: clinical correlates and risk of incident atrial fibrillation.
Article in American journal of physiology. Heart and circulatory physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Interactions of blood biomolecules with early rhythm control in atrial fibrillation patients: exploratory analysis of the EAST-AFNET 4 biomolecule study.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Trial
- Bone morphogenetic protein 10 and one-year outcomes after open revascularisation in symptomatic peripheral arterial disease or carotid stenosis.BMC cardiovascular disorders · 2026Article
- Review
- Emerging biomarkers for improved risk prediction of atrial fibrillation: potential role of bone morphogenic protein 10.American journal of physiology. Heart and circulatory physiology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
Bone morphogenetic protein-10 (BMP10), a protein predominantly secreted by atrial cardiomyocytes, has emerged as a promising biomarker in patients with atrial fibrillation (AF) and as a marker of atrial stress in patients with heart failure. Its clinical correlates in community-dwelling adults and its association with incident AF remain unexplored. BMP10 was measured in 5,883 participants from the Prevention of Renal and Vascular End-stage Disease (PREVEND) community-based cohort (mean age 53.6 yr; 51.5% females). The mean BMP10 concentration was 2.20 ± 0.43 ng/mL. In multivariable linear regression analyses, the strongest positive correlates of BMP10 were female sex [standardized beta-(Sβ): 0.34], high-density lipoprotein cholesterol (HDL-C; Sβ: 0.16), total cholesterol (Sβ: 0.13), and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.